Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer

Tanja Andrzejewski, Dorrah Deeb, Xiaohua Gao, Andrew Danyluk, Ali Syed Arbab, Scott A. Dulchavsky, Subhash C. Gautam

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Because of lack of effective treatment options for hormone-refractory prostate cancer at the present time, the need for developing novel therapeutic strategies and targets to treat and prevent the progression of hormone-sensitive prostate cancer to the hormone-refractory stage is paramount. Our previous in vitro studies have shown that curcumin sensitizes both hormone-sensitive and hormone-resistant prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that combined curcumin/TRAIL treatment induces apoptosis in cancer cells by inhibiting antiapoptotic p-Akt and nuclear factor-κB (NF-κB). In the present study, we demonstrate that curcumin and TRAIL combination regimen is also the most effective treatment for inhibiting the growth of PC3 xenografts compared to curcumin or TRAIL monotherpy. The inhibition of PC3 tumors by combined treatment correlated with significant reduction in expression of p-Akt and NF-κB in tumor tissue. Furthermore, tumor growth inhibition by curcumin/TRAIL combination regimen was associated with significant decrease in cell proliferation and an increase in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in the tumors without significant change in microvessel density. Based on the significant efficacy in this preclinical model, combined curcumin/TRAIL regimen may be an effective adjuvant therapy for hormone-refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)257-267
Number of pages11
JournalOncology Research
Volume17
Issue number6
DOIs
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Curcumin
Prostatic Neoplasms
Hormones
Neoplasms
Therapeutics
Apoptosis
DNA Nucleotidylexotransferase
Growth
Microvessels
Heterografts
Tumor Necrosis Factor-alpha
Cell Proliferation
Ligands

Keywords

  • Akt
  • Apoptosis
  • Curcumin
  • NF-κB
  • Prostate cancer
  • TRAIL

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. / Andrzejewski, Tanja; Deeb, Dorrah; Gao, Xiaohua; Danyluk, Andrew; Arbab, Ali Syed; Dulchavsky, Scott A.; Gautam, Subhash C.

In: Oncology Research, Vol. 17, No. 6, 01.12.2008, p. 257-267.

Research output: Contribution to journalArticle

Andrzejewski, T, Deeb, D, Gao, X, Danyluk, A, Arbab, AS, Dulchavsky, SA & Gautam, SC 2008, 'Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer', Oncology Research, vol. 17, no. 6, pp. 257-267. https://doi.org/10.3727/096504008786991611
Andrzejewski, Tanja ; Deeb, Dorrah ; Gao, Xiaohua ; Danyluk, Andrew ; Arbab, Ali Syed ; Dulchavsky, Scott A. ; Gautam, Subhash C. / Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. In: Oncology Research. 2008 ; Vol. 17, No. 6. pp. 257-267.
@article{97a44b19d13344d6a6e55d4b55fc3daf,
title = "Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer",
abstract = "Because of lack of effective treatment options for hormone-refractory prostate cancer at the present time, the need for developing novel therapeutic strategies and targets to treat and prevent the progression of hormone-sensitive prostate cancer to the hormone-refractory stage is paramount. Our previous in vitro studies have shown that curcumin sensitizes both hormone-sensitive and hormone-resistant prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that combined curcumin/TRAIL treatment induces apoptosis in cancer cells by inhibiting antiapoptotic p-Akt and nuclear factor-κB (NF-κB). In the present study, we demonstrate that curcumin and TRAIL combination regimen is also the most effective treatment for inhibiting the growth of PC3 xenografts compared to curcumin or TRAIL monotherpy. The inhibition of PC3 tumors by combined treatment correlated with significant reduction in expression of p-Akt and NF-κB in tumor tissue. Furthermore, tumor growth inhibition by curcumin/TRAIL combination regimen was associated with significant decrease in cell proliferation and an increase in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in the tumors without significant change in microvessel density. Based on the significant efficacy in this preclinical model, combined curcumin/TRAIL regimen may be an effective adjuvant therapy for hormone-refractory prostate cancer.",
keywords = "Akt, Apoptosis, Curcumin, NF-κB, Prostate cancer, TRAIL",
author = "Tanja Andrzejewski and Dorrah Deeb and Xiaohua Gao and Andrew Danyluk and Arbab, {Ali Syed} and Dulchavsky, {Scott A.} and Gautam, {Subhash C.}",
year = "2008",
month = "12",
day = "1",
doi = "10.3727/096504008786991611",
language = "English (US)",
volume = "17",
pages = "257--267",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "6",

}

TY - JOUR

T1 - Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer

AU - Andrzejewski, Tanja

AU - Deeb, Dorrah

AU - Gao, Xiaohua

AU - Danyluk, Andrew

AU - Arbab, Ali Syed

AU - Dulchavsky, Scott A.

AU - Gautam, Subhash C.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Because of lack of effective treatment options for hormone-refractory prostate cancer at the present time, the need for developing novel therapeutic strategies and targets to treat and prevent the progression of hormone-sensitive prostate cancer to the hormone-refractory stage is paramount. Our previous in vitro studies have shown that curcumin sensitizes both hormone-sensitive and hormone-resistant prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that combined curcumin/TRAIL treatment induces apoptosis in cancer cells by inhibiting antiapoptotic p-Akt and nuclear factor-κB (NF-κB). In the present study, we demonstrate that curcumin and TRAIL combination regimen is also the most effective treatment for inhibiting the growth of PC3 xenografts compared to curcumin or TRAIL monotherpy. The inhibition of PC3 tumors by combined treatment correlated with significant reduction in expression of p-Akt and NF-κB in tumor tissue. Furthermore, tumor growth inhibition by curcumin/TRAIL combination regimen was associated with significant decrease in cell proliferation and an increase in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in the tumors without significant change in microvessel density. Based on the significant efficacy in this preclinical model, combined curcumin/TRAIL regimen may be an effective adjuvant therapy for hormone-refractory prostate cancer.

AB - Because of lack of effective treatment options for hormone-refractory prostate cancer at the present time, the need for developing novel therapeutic strategies and targets to treat and prevent the progression of hormone-sensitive prostate cancer to the hormone-refractory stage is paramount. Our previous in vitro studies have shown that curcumin sensitizes both hormone-sensitive and hormone-resistant prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and that combined curcumin/TRAIL treatment induces apoptosis in cancer cells by inhibiting antiapoptotic p-Akt and nuclear factor-κB (NF-κB). In the present study, we demonstrate that curcumin and TRAIL combination regimen is also the most effective treatment for inhibiting the growth of PC3 xenografts compared to curcumin or TRAIL monotherpy. The inhibition of PC3 tumors by combined treatment correlated with significant reduction in expression of p-Akt and NF-κB in tumor tissue. Furthermore, tumor growth inhibition by curcumin/TRAIL combination regimen was associated with significant decrease in cell proliferation and an increase in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in the tumors without significant change in microvessel density. Based on the significant efficacy in this preclinical model, combined curcumin/TRAIL regimen may be an effective adjuvant therapy for hormone-refractory prostate cancer.

KW - Akt

KW - Apoptosis

KW - Curcumin

KW - NF-κB

KW - Prostate cancer

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=61449198651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449198651&partnerID=8YFLogxK

U2 - 10.3727/096504008786991611

DO - 10.3727/096504008786991611

M3 - Article

VL - 17

SP - 257

EP - 267

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 6

ER -